首页> 外文期刊>Pharmaceutics >The Impact of Lipid Corona on Rifampicin Intramacrophagic Transport Using Inhaled Solid Lipid Nanoparticles Surface-Decorated with a Mannosylated Surfactant
【24h】

The Impact of Lipid Corona on Rifampicin Intramacrophagic Transport Using Inhaled Solid Lipid Nanoparticles Surface-Decorated with a Mannosylated Surfactant

机译:使用经甘露糖基化表面活性剂表面修饰的吸入型固体脂质纳米颗粒,脂质体电晕对利福平的巨噬细胞内转运的影响

获取原文
           

摘要

The mimicking of physiological conditions is crucial for the success of accurate in vitro studies. For inhaled nanoparticles, which are designed for being deposited on alveolar epithelium and taken up by macrophages, it is relevant to investigate the interactions with pulmonary surfactant lining alveoli. As a matter of fact, the formation of a lipid corona layer around the nanoparticles could modulate the cell internalization and the fate of the transported drugs. Based on this concept, the present research focused on the interactions between pulmonary surfactant and Solid Lipid Nanoparticle assemblies (SLNas), loaded with rifampicin, an anti-tuberculosis drug. SLNas were functionalized with a synthesized mannosylated surfactant, both alone and in a blend with sodium taurocholate, to achieve an active targeting to mannose receptors present on alveolar macrophages (AM). Physico-chemical properties of the mannosylated SLNas satisfied the requirements relative to suitable respirability, drug payload, and AM active targeting. Our studies have shown that a lipid corona is formed around SLNas in the presence of Curosurf, a commercial substitute of the natural pulmonary surfactant. The lipid corona promoted an additional resistance to the drug diffusion for SLNas functionalized with the mannosylated surfactant and this improved drug retention within SLNas before AM phagocytosis takes place. Moreover, lipid corona formation did not modify the role of nanoparticle mannosylation towards the specific receptors on MH-S cell membrane.
机译:模仿生理条件对于准确的体外研究成功至关重要。对于设计用于沉积在肺泡上皮上并被巨噬细胞吸收的吸入纳米颗粒,研究与肺表面活性剂衬里肺泡的相互作用非常重要。实际上,在纳米颗粒周围形成脂质电晕层可以调节细胞内在化和转运药物的命运。基于此概念,本研究集中于肺表面活性剂与负载抗病毒药物利福平的固体脂质纳米颗粒组件(SLNas)之间的相互作用。用合成的甘露糖基化表面活性剂将SLNas单独或与牛磺胆酸钠混合使用,以实现对肺泡巨噬细胞(AM)上存在的甘露糖受体的主动靶向。甘露糖基化SLNas的理化性质满足有关合适的呼吸性,药物有效载荷和AM主动靶向的要求。我们的研究表明,在Curosurf(天然肺表面活性剂的商业替代品)存在下,SLNas周围会形成脂质电晕。对于用甘露糖基化的表面活性剂官能化的SLNas,脂质电晕促进了其对药物扩散的额外抵抗,并且在AM吞噬作用发生之前,这种改善的药物在SLNas中的保留。而且,脂质电晕的形成并没有改变纳米甘露糖基化作用对MH-S细胞膜上特定受体的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号